Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy

Trial Information

Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy

Subjects will be randomized to Arm A (vaccine only) or Arm B (androgen deprivation therapy
plus vaccine). On Arm A, subjects can begin the three vaccinations immediately. On Arm B,
subjects will be started on androgen deprivation therapy (ADT) 14 days prior to beginning
the vaccinations.

Subjects will be vaccinated three times, each injection administered at 30-day intervals.
Based upon our earlier clinical trial, the vaccine is considered safe and should not induce
any major side effects. The investigators hope that vaccination with this PSA virus will
cause the body to produce immunity to the PSA and that immunity will destroy any cell that
produces PSA. Since the only cells left in the body that produce PSA will be the cancer
cells, the investigators propose that the vaccination and ensuing anti-PSA immunity will
kill the prostate cancer cells. Importantly, this treatment should not cause any major side
effects as would treatment with anti-cancer drugs.

Inclusion Criteria:

- Men with prostate cancer who have received prior local therapy (radical prostatectomy
or definitive radiation therapy) and have biochemical (PSA) relapse without
evidence of radiographic or clinical metastatic disease.

- For men who had prior prostatectomy, the surgery must have occurred at least 6 months
prior to initiation of treatment.

- For men who had prior definitive radiation therapy, radiation must have been
completed at least 1 year prior to initiation of treatment.

- Exhibit at least three separate rises in serum PSA, at least one month apart with
differences >/= 0.03 ng/ml and a total PSA of >0.2 ng/ml.

- Have a PSA doubling time of >/= 6 months if the baseline serum PSA was >2 ng/ml.

- Evidence of prior or current CNS metastases. Specific imaging is not necessary in the
absence of signs or symptoms.

- Co-morbid medical conditions which would result in a life expectancy (participation)
of less than 1 year.

- Patients with compromised immune systems; congenital, acquired, or drug-induced
(immunosuppressive agents) will be excluded from the study. Use of prednisone at
doses higher than 10 mg daily (or equipotent steroid doses) for more than 7 days
within the last 3 months is not allowed.

- No-pre-existing malignancies that required treatment within the past 5 years except
for basal or squamous cell cancers of the skin.

- Prior systemic therapies for prostate cancer not allowed (hormonal therapy, including
but not limited to LHRH agonists, antiandrogens, ketoconazole or chemotherapy -
mitoxantrone/taxanes/estramustine, etc.) except when patients stopped hormone therapy
two or more years prior to enrollment and currently have normal testosterone levels;
patients in Arm B, undergoing androgen depletion therapy during the vaccination will
be eligible.

- Prior participation in any vaccine studies for non-infectious diseases.

- The inability to understand the language and the clinical protocol.

- Allergy or religious objection to pork products; Gelfoam is produced from pork.

Completion Date:

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.